moxifloxacin has been researched along with vancomycin in 136 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (vancomycin) | Trials (vancomycin) | Recent Studies (post-2010) (vancomycin) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 16,808 | 773 | 7,589 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (2.21) | 18.2507 |
| 2000's | 47 (34.56) | 29.6817 |
| 2010's | 69 (50.74) | 24.3611 |
| 2020's | 17 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Inagaki, H; Kawakami, K; Kawato, HC; Matsuhashi, N; Miyauchi, RN; Miyauchi, S; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Inagaki, H; Takahashi, H; Takemura, M | 1 |
| Appelbaum, PC; Bhawsar, SB; Bozdogan, B; de Souza, NJ; Desai, VN; Deshpande, PK; Gupte, SV; Hooper, DC; Jacobs, MR; Jha, R; Khorakiwala, HF; Patel, MV; Shetty, N; Shukla, MC; Strahilevitz, J; Yeole, RD | 1 |
| Cars, O; Karlsson, MO; Löwdin, E; Nielsen, EI; Sandström, M; Viberg, A | 1 |
| Duewelhenke, N; Eysel, P; Krut, O | 1 |
| Frank, KL; Patel, R; Piper, KE; Reichert, EJ | 1 |
| Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
| Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Hashimoto, A; Lucien, E; Marlor, CW; Nelson, DM; Ou, Y; Pais, GC; Podos, SD; Pucci, MJ; Song, Y; Thanassi, JA; Thoma, CL; Wang, Q; Wiles, JA | 1 |
| Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Mushtaq, G; Podos, SD; Pucci, MJ; Thanassi, JA; Thoma, CL; Vigliotti, GA | 1 |
| Cottagnoud, M; Cottagnoud, P; Schaffner, T; Stucki, A; Winkelmann, V | 1 |
| Chang, CL; Jeong, J; Jeong, SH; Jung, HJ; Kim, HR; Kim, S; Lee, EY; Lee, JN; Shin, JH | 1 |
| Galang, MA; Gerding, DN; Hecht, DW; Johnson, S; Osmolski, JR; Sambol, SP | 1 |
| Arvieux, C; Bugnon, D; Caillon, J; Grossi, O; Hamel, A; Jacqueline, C; Potel, G | 1 |
| Ardanuy, C; Bouza, E; Calatayud, L; Cercenado, E; Fenoll, A; Liñares, J; Martín, R; Pallares, R | 1 |
| Baudry, PJ; DeCorby, M; Hoban, DJ; Johnson, J; Karlowsky, JA; Lagacé-Wiens, P; Laing, N; McCracken, M; Mulvey, MR; Nichol, KA; Tailor, F; Vashisht, R; Walkty, A; Weshnoweski, B; Wierzbowski, A; Zhanel, GG | 1 |
| Chang, KY; Ho, YH; Hsieh, YC; Hsueh, PR; Huang, LM; Huang, YC; Lin, HC | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| del Pozo, JL; Mandrekar, JN; Patel, R; Rouse, MS; Sampedro, MF; Steckelberg, JM | 1 |
| Karlowsky, JA; Laing, NM; Zhanel, GG | 1 |
| Jacobus, NV; McDermott, LA; Snydman, DR | 1 |
| Appelbaum, PC; Bhagwat, SS; Kosowska-Shick, K; McGhee, P; Patel, MV | 1 |
| Denis, O; Nguyen, HA; Struelens, MJ; Theunis, A; Tulkens, PM; Van Bambeke, F; Vergison, A | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Brunner, LS; Haas, W; Lee, JC; Morris, TW; Pillar, CM; Zurenko, GE | 1 |
| Amaral, K; Dzink-Fox, J; Fischer, E; Goldovitz, J; Manni, K; Neckermann, G; Osborne, CS; Pecanka, R; Ryder, NS; Yu, D | 1 |
| Inagaki, H; Ito, M; Kawakami, K; Matsuhashi, N; Miyauchi, R; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Bowker, KE; Caspers, P; Gaucher, B; MacGowan, AP | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cai, L; Gilbert, GL; Kong, F; Oftadeh, S; Xiao, M; Xu, X; Zhou, F | 1 |
| Chen, HC; King, CH; Lai, JF; Lauderdale, TL; Shiau, YR | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Amsler, KM; Bush, K; Foleno, BD; He, W; Lynch, AS; Macielag, MJ; Morrow, BJ | 1 |
| Bajaksouzian, S; Biek, D; Critchley, IA; Good, CE; Jacobs, MR; Jones, RN; Sader, HS; Windau, AR | 1 |
| Ardanuy, C; Brito-Avô, A; Gonçalo-Marques, J; Liñares, J; Morais, A; Pires, R; Rolo, D; Santos-Sanches, I | 1 |
| Chong, Y; Jeong, SH; Kim, MS; Lee, K; Lee, Y; Park, Y; Yong, D | 1 |
| Parra-Ruiz, J; Rose, WE; Rybak, MJ; Vidaillac, C | 1 |
| Baek, SY; Chae, SE; Cho, YL; Jeong, JW; Jung, SJ; Kim, YZ; Kwak, JH; Lee, HH; Lee, HS; Park, TK; Woo, SH | 1 |
| Bradbury, BJ; Deshpande, M; Hashimoto, A; Kim, HY; Lucien, E; Nelson, DM; Pais, GC; Podos, SD; Pucci, MJ; Thanassi, JA; Wang, Q; Wiles, JA | 1 |
| Bradbury, BJ; Deshpande, M; Phadke, AS; Pucci, MJ; Thanassi, JA; Wiles, JA | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Bao, Y; Huang, X; Lan, S; Wang, T; Zhang, X; Zhu, S | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Lynch, AS; Ma, Z | 1 |
| Domalaon, R; Gorityala, BK; Goswami, S; Idowu, T; Lyu, Y; Schweizer, F; Shan, A; Yang, X; Zhanel, GG | 1 |
| Eswaran, S; Narayanan, S; Shivarudraiah, P; Shruthi, TG; Subramanian, S | 1 |
| Bishai, WR; Duan, G; Gunosewoyo, H; Liu, LL; Lun, S; Tang, J; Xiao, S; Yang, F; Yu, LF; Zhang, W | 1 |
| Caljon, G; Cappoen, D; Claes, P; Cools, F; Cos, P; De Kimpe, N; de Macedo, MB; Delputte, P; Holvoet, F; Maes, L; Mangelinckx, S; Matheeussen, A; Meiresonne, T; Neyrolles, O; Piller, T; Semina, E; Torfs, E; Van Calster, K | 1 |
| Xu, Z | 1 |
| Adeniyi, ET; Chen, S; Drießen, D; Ioerger, TR; Kalscheuer, R; Kruppa, M; Müller, TJJ; Rehberg, N; Sommer, GA; Tasch, BOA; Wang, L; Wolf, K; Zhu, K | 1 |
| Hoban, DJ; Karlowsky, JA; Zhanel, GG | 1 |
| Frimodt-Møller, N; Knudsen, JD; Ostergaard, C; Sørensen, TK | 1 |
| Heisig, P; Jones, ME; Klootwijk, M; Schmitz, FJ; Verhoef, J; Visser, MR | 1 |
| Bottura, P; Capra, R; Maggiolo, F; Migliorino, M; Pravettoni, G; Suter, F | 1 |
| Longworth, DL | 1 |
| Georgopoulos, A; Graninger, W; Grisold, A; Mueller-Uri, P; Presterl, E | 1 |
| Entenza, JM; Glauser, MP; Moreillon, P; Que, YA; Vouillamoz, J | 1 |
| Blandino, G; Caccamo, F; Milazzo, I; Musumeci, R; Nicoletti, G; Speciale, A | 1 |
| Gottlieb, T; Leroi, MJ; Siarakas, S | 1 |
| Abb, J | 1 |
| Barton, T; Bowlware, K; Hardy, RD; Iglehart, J; Katz, K; McCoig, CC; McCracken, GH; Michelow, IC; Rodriguez-Cerrato, V; Saavedra, J | 1 |
| Cassone, M; Monaco, M; Pompeo, ME; Tarasi, A; Tarasi, D; Venditti, M | 1 |
| Buchheidt, D; Hofheinz, R; Hummel, M | 1 |
| Tipperman, R | 1 |
| Aliprandis, E; Ciralsky, J; Herling, I; Katz, HR; Lai, H | 1 |
| Gordon, YJ; Kowalski, RP; Mah, FS; Romanowski, EG; Yates, KA | 1 |
| Beckmann, J; Kalteis, T; Lehn, N; Lerch, K; Linde, HJ; Schaumburger, J; Schröder, HJ | 1 |
| Beckmann, J; Grifka, J; Handel, M; Kalteis, T; Lehn, N; Lerch, K; Schröder, HJ | 1 |
| Flynn, HW; Harper, T; Miller, D | 1 |
| Cetinkaya, Z; Ermis, SS; Inan, UU; Kiyici, H; Ozturk, F | 1 |
| Jhanji, V; Satpathy, G; Sharma, N; Titiyal, J | 1 |
| Delgado, J; Diaz, LA; Galvis, V; Gómez, AJ; Tello, A; Valencia, F | 1 |
| Donta, I; Galani, L; Giamarellou, H; Iliopoulos, D; Karayiannakos, P; Pefanis, A; Sakka, V; Skiadas, I; Triantafyllidi, H | 1 |
| Adebambo, B; Senthilvel, E; Shah, C | 1 |
| Brooks, CW; Demartelaere, SL; Johnson, AJ | 1 |
| Banaszkiewicz, A; Młynarczyk, G; Obuch-Woszczatyński, P; Pituch, H; Radzikowski, A; Wultańska, D | 1 |
| Ahmed, GF; Elkhatib, WF; Noreddin, AM; Salem, AH | 1 |
| Kim, JY; Kim, SY | 1 |
| Hsueh, PR; Huang, YT; Ko, WC; Lee, NY; Lee, TF; Liao, CH; Lin, SY; Lin, YC; Tsai, PJ | 1 |
| Cars, O; Friberg, LE; Nielsen, EI | 2 |
| Hartmann, B; Keller, F; Maus, S; Rothermund, L | 1 |
| Amann, K; Bröcker, EB; Müller, PA; Trautmann, A | 1 |
| Armstrong, BK; Kim, SJ; Mehta, S | 1 |
| Hooper, CY; Khan, A; Lightman, SL; Pacheco, P; Tam, PM; Taylor, SR | 1 |
| Hsueh, PR; Ko, WC; Liao, CH; Lu, JJ | 1 |
| Leggio, M; Podos, SD; Pucci, MJ; Thanassi, JA | 1 |
| Chen, CM; Cheng, YJ; Chuang, YC; Hsu, GJ; Hsueh, PR; Jang, TN; Kung, HC; Li, CF; Liao, CH; Lin, HC; Liu, MF; Liu, YC; Shi, ZY; Tsao, SM; Wang, LS | 1 |
| Bosjolie, A; Qiao, M; Shih, CY; Udell, IJ | 1 |
| Herrinton, LJ; Shorstein, NH; Winthrop, KL | 1 |
| Blanco, AR; Papa, V; Spoto, CG; Sudano Roccaro, A | 1 |
| Blanco, C; Núñez, MX | 1 |
| Nguyen, ET; Shorstein, NH | 1 |
| Rudnisky, CJ; Wan, D; Weis, E | 1 |
| Goering, RV; Lynn, AN; Persing, DH; Tenover, FC; Tickler, IA; Whitmore, JD | 1 |
| Aggarwal, H; Ahmed, S; Edwards, P; Gao, H; Kuruvilla, O; Li, Y; Qiao, X; Yee, DC | 1 |
| Hegarty, JP; Jayarao, BM; Lumadue, J; Stewart, DB; Varshney, JB; Venkitanarayanan, K; Very, KJ; Williams, JL | 1 |
| Braga-Mele, R; Chang, DF; Henderson, BA; Mamalis, N; Talley-Rostov, A; Vasavada, A | 1 |
| Carter, GP; Elliott, B; Howden, BP; Jenkin, GA; Korman, TM; Kotsanas, D; Lyras, D; Mackin, KE; Riley, TV; Rood, JI | 1 |
| Buyck, JM; Peyrusson, F; Tulkens, PM; Van Bambeke, F | 1 |
| Forbes, BA; Gerding, DN; Goldstein, EJ; Jacobus, NV; Jenkins, SG; Johnson, S; McDermott, LA; Mirrett, S; Patel, R; Snydman, DR; Stone, S; Thorpe, C | 1 |
| Freeman, J; Vernon, J; Vickers, R; Wilcox, MH | 1 |
| Fulcher, LC; Johnson, D; Jorgensen, J; Kiel, JW; McElmeel, ML; Montes, JA | 1 |
| Banta, JT; Flynn, HW; Schimel, AM; Stringham, JD | 1 |
| del Mar Gamboa-Coronado, M; López-Ureña, D; Montoya-Ramírez, M; Quesada-Gómez, C; Rodríguez, C; Rodríguez-Cavallini, E; Somogyi, T | 1 |
| Casey, M; Igawa, G; Koike, R; Moriya, K; Nukui, Y; Okugawa, S; Saito, R; Sawabe, E; Tohda, S | 1 |
| Bailey, R; Haller, JA; Hark, LA; Roman, JS; Tyson, SL; Zhan, T | 1 |
| Kriz, Z; Krutova, M; Kubicek, L; Kuijper, E; Matejkova, J; Nyc, O; Ruzicka, F; Tejkalova, R | 1 |
| Dong, J; Johnson, DW; Qu, Z; Tian, X; Wang, H; Xu, R; Yang, Z | 1 |
| Cheng, JW; Kong, F; Kudinha, T; Liao, JW; Xiao, M; Xu, YC; Yang, QW; Yu, SY; Zhou, ML | 1 |
| Libre, PE; Mathews, S | 1 |
| Pujari, A; Singh, R; Temkar, S; Urkude, J | 1 |
| Chen, YB; Fang, YH; Gu, SL; Li, LJ; Lv, T; Shen, P; Tang, LL | 1 |
| Ambati, BK; Bardsley, T; Bondalapati, S; Bowen, RC; Evans, PR; Greene, T; Kliethermes, M; Lawyer, TW; Mamalis, CA; McFarland, M; Rudnisky, CJ; Shi, D; Snow, KB; Zhou, AX | 1 |
| Peyrusson, F; Tulkens, PM; Van Bambeke, F | 1 |
| Araj, GF; Becker, SL; Berger, FK; Bischoff, M; Dbaibo, G; Gärtner, B; Karaoui, WR; Mahfouz, R; Matar, GM; Rasheed, SS; Rimmani, HH; Sharara, AI; von Müller, L | 1 |
| Bernardy, J; Faldyna, M; Krejčí, J; Krutova, M; Matejkova, J; Nyc, O; Tkadlec, J; Zouharova, M | 1 |
| Galvis, V; Gómez, MA; Grice, JM; Niño, CA; Tello, A | 1 |
| Berger, F; Jazmati, N; Piepenbrock, E; Stelzer, Y | 1 |
| Chalam, KV; Ng, C | 1 |
| Heidary, G; Somsen, D | 1 |
| Baba, T; Inoue, Y; Matsuura, K; Miyake, H; Miyazaki, D; Sasaki, SI; Shimizu, Y | 1 |
| Arshinoff, SA; Felfeli, T; Modabber, M | 1 |
| Atta, S; Bhat, AK; Dhaliwal, D; Durrani, AF; Jhanji, V; Kowalski, RP; Mammen, A | 1 |
| Cheng, JW; Fan, X; Hou, X; Kudinha, T; Liang, GW; Liu, C; Shao, DH; Su, JR; Wang, Y; Wei, M; Xiao, M; Xiong, ZJ; Xu, YC; Yang, CX; Yang, QW; Yu, SY | 1 |
| Chhabria, M; Kudaravalli, P; Lesho, E; Pendela, VS | 1 |
| Ho, AC; Patel, SN; Peck, TJ | 1 |
| Bhojwani, D | 1 |
| Chen, HC; Chen, KJ; Chen, YP; Chong, YJ; Kang, EY; Lai, CC; Liu, L; Sun, MH; Wu, WC | 1 |
| Jane, F; Jon J, V; Mark H, W | 1 |
| Gurnani, B; Kannusamy, V; Kaur, K; Yadalla, D | 1 |
| Das, S; Gunasekaran, R; Mitra, S; Mohamed, A; Prajna, L; Prajna, NV; Sharma, S; Soni, T | 1 |
| Corrales, MI; Galvis, V; Garcia, D; Parra, MM; Rangel, CM; Sánchez-Ávila, R; Tello, A; Varón, CL; Villareal, E; Villarreal, D | 1 |
| Adamczyk, M; Albrecht, V; Anderson, KF; Campbell, D; Elkins, CA; Gargis, AS; Guh, AY; Halpin, AL; Karlsson, M; Kent, AG; Korhonen, LC; Lutgring, JD; McAllister, G; McDonald, LC; McKay, SL; Paulick, AL; Rasheed, JK; Vlachos, N | 1 |
| Horita, N; Kaneko, T; Kato, A; Masuhara, N; Mizuki, N; Namkoong, H; Nomura, E; Takeuchi, M | 1 |
| Li, J; Li, N; Liu, B; Lü, X; Wang, H; Zhang, Y | 1 |
| Cherney, EF; Daniels, AB; Kim, SJ; Law, JC; Patel, SN; Taubenslag, KJ | 1 |
10 review(s) available for moxifloxacin and vancomycin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1,2,3-Triazole-containing hybrids with potential antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Anti-Bacterial Agents; Drug Design; Methicillin-Resistant Staphylococcus aureus; Triazoles | 2020 |
Microbial drug resistance and the roles of the new antibiotics.
Topics: Acetamides; Anti-Infective Agents; Atovaquone; Aza Compounds; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Enterococcus; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Methicillin Resistance; Moxifloxacin; Naphthoquinones; Oxazolidinones; Proguanil; Pseudomonas aeruginosa; Quinolines; Staphylococcus aureus; Streptococcus pneumoniae; Vancomycin; Vancomycin Resistance; Virginiamycin | 2001 |
Pharmacologic considerations for cataract surgery.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Cataract Extraction; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ophthalmic Solutions; Quinolines; Triamcinolone Acetonide; Vancomycin | 2004 |
Intracameral antibiotics: Safety, efficacy, and preparation.
Topics: Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract Extraction; Cephalosporins; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Pharmaceutical Preparations; Treatment Outcome; Vancomycin | 2014 |
Clinical outcomes after injection of a compounded pharmaceutical for prophylaxis after cataract surgery: a large-scale review.
Topics: Anti-Bacterial Agents; Drug Compounding; Drug Therapy, Combination; Endophthalmitis; Fluoroquinolones; Glucocorticoids; Humans; Intravitreal Injections; Moxifloxacin; Phacoemulsification; Postoperative Complications; Treatment Outcome; Triamcinolone Acetonide; Vancomycin | 2017 |
Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis.
Topics: Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract Extraction; Cefuroxime; Endophthalmitis; Eye Infections, Bacterial; Humans; Injections, Intraocular; Intraoperative Period; Moxifloxacin; Vancomycin | 2018 |
Topical insulin in neurotrophic keratopathy after resection of acoustic neuroma.
Topics: Administration, Ophthalmic; Anti-Bacterial Agents; Combined Modality Therapy; Contact Lenses, Hydrophilic; Corneal Ulcer; Facial Nerve Injuries; Facial Paralysis; Female; Humans; Insulin; Keratitis; Middle Aged; Moxifloxacin; Neuroma, Acoustic; Postoperative Complications; Staphylococcal Infections; Trigeminal Nerve Injuries; Vancomycin | 2019 |
Endophthalmitis after cataract surgery: an update on recent advances.
Topics: Anti-Bacterial Agents; Cataract Extraction; Drug Implants; Endophthalmitis; Eye Infections, Bacterial; Humans; Moxifloxacin; Postoperative Complications; Vancomycin; Vitrectomy; Vitreous Body | 2021 |
Prophylactic antibiotics for postcataract surgery endophthalmitis: a systematic review and network meta-analysis of 6.8 million eyes.
Topics: Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract Extraction; Cefuroxime; Endophthalmitis; Humans; Moxifloxacin; Network Meta-Analysis; Postoperative Complications; Vancomycin | 2022 |
1 trial(s) available for moxifloxacin and vancomycin
| Article | Year |
|---|---|
Intraperitoneal Vancomycin Plus Either Oral Moxifloxacin or Intraperitoneal Ceftazidime for the Treatment of Peritoneal Dialysis-Related Peritonitis: A Randomized Controlled Pilot Study.
Topics: Administration, Oral; Anti-Bacterial Agents; Ceftazidime; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Peritoneal Dialysis; Peritoneum; Peritonitis; Pilot Projects; Prospective Studies; Vancomycin | 2017 |
125 other study(ies) available for moxifloxacin and vancomycin
| Article | Year |
|---|---|
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
Topics: Anti-Bacterial Agents; Cyclopropanes; Drug Resistance, Bacterial; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Stereoisomerism; Structure-Activity Relationship | 2003 |
Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position.
Topics: Anti-Infective Agents; Cyclopropanes; DNA Topoisomerase IV; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2004 |
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Dogs; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Mutation; Prodrugs; Quinolizines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Vancomycin Resistance | 2005 |
Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.
Topics: Algorithms; Anti-Bacterial Agents; Aza Compounds; Cefuroxime; Dose-Response Relationship, Drug; Erythromycin; Fluoroquinolones; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Penicillin G; Quinolines; Streptococcus pyogenes; Vancomycin | 2007 |
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Antimycin A; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Chloramphenicol; Clindamycin; Dose-Response Relationship, Drug; Fluoroquinolones; Glycolysis; HeLa Cells; Humans; Lactic Acid; Linezolid; Macrolides; Mitochondria; Osteoblasts; Oxazolidinones; Rotenone; Tetracyclines; Time Factors | 2007 |
In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
Topics: Acetamides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Biofilms; DNA, Bacterial; Humans; Linezolid; Microbial Sensitivity Tests; Nafcillin; Oxazolidinones; Penicillin-Binding Proteins; Penicillins; Reverse Transcriptase Polymerase Chain Reaction; Staphylococcal Infections; Staphylococcus; Tetracycline | 2007 |
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
Topics: Animals; Anti-Bacterial Agents; Cell Line, Tumor; Drug Resistance, Multiple, Bacterial; Female; Humans; Methicillin Resistance; Mice; Quinolones; Staphylococcus aureus; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 2007 |
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
Topics: Animals; Anti-Infective Agents; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Mice; Microbial Sensitivity Tests; Quinolones; Thiazoles | 2007 |
Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall.
Topics: Animals; Anti-Bacterial Agents; Bacteriolysis; Ceftriaxone; Cell Wall; Cerebrospinal Fluid; Choline; Daptomycin; Disease Models, Animal; Humans; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Penicillin Resistance; Rabbits; Streptococcus pneumoniae; Treatment Outcome; Tritium | 2007 |
Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Genes, Bacterial; Hospitals; Humans; Korea; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Molecular Epidemiology; Mutation; Ofloxacin; Pneumococcal Infections; Polymerase Chain Reaction; Prevalence; Reserpine; Respiratory Tract Infections; Retrospective Studies; Streptococcus pneumoniae | 2007 |
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Humans; Microbial Sensitivity Tests; United States | 2007 |
In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
Topics: Animals; Anti-Bacterial Agents; Arthritis, Experimental; Arthritis, Infectious; Aza Compounds; Cloxacillin; Colony Count, Microbial; Fluoroquinolones; Half-Life; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Vancomycin | 2007 |
Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain.
Topics: Anti-Bacterial Agents; Clone Cells; Drug Resistance, Multiple, Bacterial; Electrophoresis, Polyacrylamide Gel; Erythromycin; Genes, Bacterial; Microbial Sensitivity Tests; Phenotype; Pneumococcal Infections; Serotyping; Spain; Streptococcus pneumoniae; Tetracycline Resistance | 2007 |
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; Canada; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Population Surveillance | 2008 |
Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Genotype; Humans; Microbial Sensitivity Tests; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; Taiwan | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
Topics: Anti-Infective Agents; Biofilms; Bioreactors; Electricity; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Staphylococcus aureus; Staphylococcus epidermidis | 2009 |
In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Cross Infection; Enterocolitis, Pseudomembranous; Glycosides; Humans; In Vitro Techniques; Microbial Sensitivity Tests | 2008 |
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; Carbapenems; Doripenem; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests | 2008 |
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
Topics: Anti-Bacterial Agents; Cross Infection; Drug Resistance, Bacterial; Fluoroquinolones; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Quinolones; Staphylococcal Infections; Staphylococcus aureus; United States; Vancomycin Resistance | 2009 |
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
Topics: Anti-Bacterial Agents; Cell Line; Cystic Fibrosis; Dose-Response Relationship, Drug; Fusidic Acid; Gentamicins; Humans; Macrophages; Microbial Sensitivity Tests; Oxacillin; Phenotype; Protein Binding; Staphylococcus aureus; Thymidine | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
Topics: Anti-Bacterial Agents; Azepines; Bacteria, Anaerobic; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests | 2009 |
In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
Topics: Acetamides; Amidohydrolases; Animals; Anti-Infective Agents; Female; Linezolid; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Structure; Oxazolidinones; Peptides; Pneumonia; Staphylococcus aureus; Streptococcus pneumoniae; Thigh | 2009 |
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
Topics: Anti-Bacterial Agents; Drug Design; Drug Resistance, Multiple; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 2009 |
In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
Topics: Folic Acid Antagonists; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Phthalazines; Staphylococcus aureus; Streptococcus | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Child, Preschool; DNA Transposable Elements; Drug Resistance, Bacterial; Erythromycin; Genotype; Humans; Macrolides; Microbial Sensitivity Tests; New South Wales; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae | 2010 |
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Quinolones; Taiwan | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Design; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Methicillin-Resistant Staphylococcus aureus; Streptococcus pneumoniae | 2010 |
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Communicable Diseases, Emerging; Drug Resistance, Multiple, Bacterial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; United States | 2010 |
Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Outer Membrane Proteins; Bacterial Typing Techniques; Carrier Proteins; Child; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Molecular Epidemiology; Norfloxacin; Point Mutation; Portugal; Streptococcal Infections; Streptococcus pyogenes | 2010 |
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria, Anaerobic; Bacteroides fragilis; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Positive Cocci; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Republic of Korea | 2010 |
Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
Topics: Anti-Bacterial Agents; Aza Compounds; Biofilms; Clarithromycin; Daptomycin; Fluoroquinolones; Microscopy, Electron, Scanning; Moxifloxacin; Quinolines; Rifampin; Staphylococcus aureus; Vancomycin | 2010 |
In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Bacterial Infections; Gram-Positive Bacteria; Linezolid; Male; Mice; Mice, Inbred ICR; Oxazolidinones; Staphylococcus aureus; Vancomycin | 2010 |
Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Anti-Bacterial Agents; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Escherichia coli; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pyrrolidines; Quinolones; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 2011 |
Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
Topics: Anti-Bacterial Agents; Cell Line, Tumor; DNA Topoisomerase IV; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Methicillin-Resistant Staphylococcus aureus; Organoselenium Compounds; Piperidines; Quinolines; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Topoisomerase II Inhibitors | 2011 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogens.
Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Structure; Penicillin Resistance; Streptococcus pneumoniae; Streptococcus pyogenes; Structure-Activity Relationship | 2015 |
Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Rifamycins; Staphylococcus aureus; Structure-Activity Relationship | 2016 |
Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Hemolysis; Lysine; Microbial Sensitivity Tests; Minocycline; Models, Biological; Rifampin; Tobramycin | 2017 |
Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Structure; Mycobacterium tuberculosis; Oxadiazoles; Quinolines; Structure-Activity Relationship | 2019 |
Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Coumarins; Crystallography, X-Ray; Drug Resistance, Bacterial; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Polyketide Synthases; Structure-Activity Relationship; Vero Cells | 2019 |
The synthesis and in vitro biological evaluation of novel fluorinated tetrahydrobenzo[j]phenanthridine-7,12-diones against Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Benzophenanthridines; Cell Line; Dose-Response Relationship, Drug; Humans; Hydrocarbons, Fluorinated; Macrophages; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship | 2019 |
Nature-Inspired (di)Azine-Bridged Bisindole Alkaloids with Potent Antibacterial
Topics: Alkaloids; Animals; Anti-Bacterial Agents; Cell Line; Cell Survival; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Indoles; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Peritonitis; Pyruvate Kinase; Rabbits | 2020 |
In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Drug Resistance, Microbial; Enterococcus; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Vancomycin | 1998 |
Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ceftriaxone; Cephalosporins; Drug Evaluation; Fluoroquinolones; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Moxifloxacin; Penicillin Resistance; Protein Binding; Quinolines; Quinolones; Rabbits; Streptococcus pneumoniae; Time Factors; Vancomycin | 1998 |
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-re
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus; Vancomycin; Virginiamycin | 1999 |
In-vitro activity of moxifloxacin combined with other antibacterials against methicillin-resistant Staphylococcus aureus.
Topics: Anti-Infective Agents; Aza Compounds; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Gentamicins; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rifampin; Staphylococcus aureus; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin | 2000 |
Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
Topics: Acetamides; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Base Sequence; Ciprofloxacin; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Oxazolidinones; Polymerase Chain Reaction; Quinolines; Sensitivity and Specificity; Staphylococcus aureus; Teicoplanin; Vancomycin | 2001 |
Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; Drug Resistance, Microbial; Endocarditis, Bacterial; Fluoroquinolones; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rats; Spleen; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2001 |
Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates.
Topics: Aerobiosis; Anaerobiosis; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteria; Ceftriaxone; Cephalosporins; Ciprofloxacin; Clindamycin; Clostridium; Drug Resistance, Multiple, Bacterial; Erythromycin; Fluoroquinolones; Imipenem; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma; Quinolines; Streptococcus; Teicoplanin; Thienamycins; Vancomycin | 2002 |
E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid.
Topics: Acetamides; Anti-Infective Agents; Aza Compounds; Clostridioides difficile; Clostridium Infections; Cross Infection; Diarrhea; Fluoroquinolones; Fusidic Acid; Gatifloxacin; Humans; Linezolid; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Oxazolidinones; Quinolines; Sensitivity and Specificity; Vancomycin | 2002 |
In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Mupirocin; Oxazolidinones; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Teicoplanin; Vancomycin; Virginiamycin | 2002 |
Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Indoles; Male; Meningitis, Bacterial; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Quinolones; Rabbits; Streptococcus pneumoniae; Vancomycin; Vancomycin Resistance | 2003 |
Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
Topics: Anti-Infective Agents; Aza Compounds; Catheterization; Device Removal; Drug Interactions; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Glycopeptides; Humans; Italy; Male; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Risk Assessment; Sensitivity and Specificity; Staphylococcal Infections; Staphylococcus aureus; Teicoplanin; Treatment Failure; Vancomycin; Vancomycin Resistance | 2003 |
Severe Chlamydia pneumoniae infection in a patient with mild neutropenia during treatment of Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aza Compounds; Bleomycin; Chlamydophila Infections; Chlamydophila pneumoniae; Dacarbazine; Doxorubicin; Drug Therapy, Combination; Female; Fluoroquinolones; Hodgkin Disease; Humans; Imipenem; Immunocompromised Host; Moxifloxacin; Neutropenia; Pneumonia, Bacterial; Quinolines; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin; Vincristine | 2004 |
Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Keratitis; Methicillin Resistance; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2005 |
Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model.
Topics: Animals; Anterior Chamber; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Injections; Moxifloxacin; No-Observed-Adverse-Effect Level; Ophthalmic Solutions; Quinolines; Rabbits; Safety; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Vancomycin; Vitreous Body | 2005 |
Treatment of implant-associated infections with moxifloxacin: an animal study.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Biofilms; Fluoroquinolones; Implants, Experimental; Male; Moxifloxacin; Osteomyelitis; Quinolines; Rats; Rats, Wistar; Staphylococcal Infections; Vancomycin | 2006 |
Moxifloxacin superior to vancomycin for treatment of bone infections--a study in rats.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Femur; Fluoroquinolones; Male; Moxifloxacin; Osteomyelitis; Quinolines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2006 |
In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.
Topics: Acetamides; Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Biological Availability; Coagulase; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Microbiological Techniques; Moxifloxacin; Oxazolidinones; Quinolines; Staphylococcal Infections; Staphylococcus; Vancomycin; Virginiamycin | 2007 |
Effects of intravitreal moxifloxacin and dexamethasone in experimental Staphylococcus aureus endophthalmitis.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Aza Compounds; Colony Count, Microbial; Dexamethasone; Drug Evaluation, Preclinical; Drug Therapy, Combination; Edema; Endophthalmitis; Fluoroquinolones; Hyperemia; Injections; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Vancomycin; Vitreous Body | 2007 |
Fourth-generation fluoroquinolone-resistant bacterial keratitis.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Corneal Ulcer; Drug Resistance, Bacterial; Drug Therapy, Combination; Eye Infections, Bacterial; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Staphylococcal Infections; Staphylococcus epidermidis; Tobramycin; Vancomycin | 2007 |
Late bacterial keratitis after intracorneal ring segments (Ferrara ring) insertion for keratoconus.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Corneal Stroma; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Imipenem; Keratoconus; Microbial Sensitivity Tests; Moxifloxacin; Postoperative Complications; Prostheses and Implants; Prosthesis Implantation; Quinolines; Staphylococcal Infections; Vancomycin | 2007 |
Successful treatment with moxifloxacin of experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Animals; Anti-Bacterial Agents; Aortic Valve; Aza Compounds; Disease Models, Animal; Endocarditis, Bacterial; Female; Fluoroquinolones; Heart Valve Diseases; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Treatment Outcome; Vancomycin | 2009 |
Red eye, blurry vision, and cough.
Topics: Anti-Infective Agents; Aortic Valve; Aortic Valve Insufficiency; Aza Compounds; Blindness; Ceftriaxone; Cough; Echocardiography, Transesophageal; Endophthalmitis; Fever; Fluoroquinolones; Hearing Loss, Sensorineural; Heart Valve Prosthesis; Humans; Male; Middle Aged; Mitral Valve; Moxifloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae; Vancomycin; Vision Disorders | 2010 |
Spontaneous subconjunctival abscess because of Haemophilus influenzae.
Topics: Abscess; Adult; Anti-Infective Agents; Aza Compounds; Conjunctival Diseases; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Moxifloxacin; Quinolines; Tobramycin; Tomography, X-Ray Computed; Vancomycin | 2010 |
[Prevalence of Clostridium difficile in the gastrointestinal tract of hospitalized children under two years of age].
Topics: Aza Compounds; Ciprofloxacin; Clindamycin; Clostridioides difficile; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Female; Fluoroquinolones; Gastrointestinal Tract; Gatifloxacin; Genotype; Humans; Infant; Infant, Newborn; Male; Metronidazole; Moxifloxacin; Phenotype; Quinolines; Species Specificity; Vancomycin | 2010 |
Pharmacodynamics of moxifloxacin versus vancomycin against biofilms of methicillin-resistant Staphylococcus aureus and epidermidis in an in vitro model.
Topics: Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Biofilms; Fluoroquinolones; In Vitro Techniques; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Quinolines; Staphylococcus epidermidis; Vancomycin | 2010 |
Prophylactic effect of intravenous moxifloxacin in a rabbit model of Staphylococcus epidermidis endophthalmitis.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Injections, Intravenous; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Staphylococcus epidermidis; Vancomycin | 2011 |
Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Clostridioides difficile; Fluoroquinolones; Genotype; Metronidazole; Microbial Sensitivity Tests; Molecular Epidemiology; Moxifloxacin; Polymerase Chain Reaction; Quinolines; Ribotyping; Taiwan; Vancomycin | 2011 |
Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model.
Topics: Anti-Bacterial Agents; Aza Compounds; Cefuroxime; Erythromycin; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Penicillin G; Quinolines; Streptococcus pyogenes; Vancomycin | 2011 |
Thrombocytopenia, INR prolongation and fall in fibrinogen under daptomycin.
Topics: Anti-Bacterial Agents; Aza Compounds; Daptomycin; Endocarditis, Bacterial; Fibrinogen; Fluoroquinolones; Humans; International Normalized Ratio; Male; Middle Aged; Moxifloxacin; Quinolines; Renal Dialysis; Staphylococcal Infections; Staphylococcus epidermidis; Thrombocytopenia; Vancomycin | 2011 |
Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.
Topics: Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Cefuroxime; Computer Simulation; Erythromycin; Escherichia coli; Fluoroquinolones; Gentamicins; Humans; Microbial Sensitivity Tests; Moxifloxacin; Penicillin G; Quinolines; Streptococcus pyogenes; Vancomycin | 2011 |
[Maculo-papular exanthem with acute renal failure. Drug-induced hypersensitivity syndrome].
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aortic Valve; Aza Compounds; Biopsy; Diagnosis, Differential; Drug Eruptions; Drug Therapy, Combination; Endocarditis, Bacterial; Eosinophilia; Fluoroquinolones; Glucocorticoids; Humans; Kidney; Legionnaires' Disease; Male; Meropenem; Moxifloxacin; Nephritis, Interstitial; Quinolines; Sepsis; Skin; Thienamycins; Vancomycin | 2012 |
Vancomycin, ceftazidime, and moxifloxacin can be safely stored in single-use, polypropylene syringes.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Ceftazidime; Drug Stability; Drug Storage; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Polypropylenes; Quinolines; Syringes; Temperature; Vancomycin | 2011 |
Adjunctive antibiotics in the treatment of acute bacterial endophthalmitis following cataract surgery.
Topics: Acute Disease; Administration, Oral; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Bacteria; Cataract Extraction; Ciprofloxacin; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Postoperative Complications; Quinolines; Retrospective Studies; Vancomycin; Visual Acuity; Vitreous Body | 2012 |
Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.
Topics: Anti-Infective Agents; Aza Compounds; Bacterial Proteins; Clostridioides difficile; Fluoroquinolones; Gemifloxacin; Glycosides; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Rifamycins; Rifaximin; Taiwan; Vancomycin | 2012 |
Bactericidal activity of ACH-702 against nondividing and biofilm Staphylococci.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Biofilms; Fluoroquinolones; Linezolid; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Oxazolidinones; Quinolines; Quinolones; Rifampin; Staphylococcus; Thiazoles; Vancomycin | 2012 |
Changing trends in antimicrobial susceptibility of Streptococcus pneumoniae isolates in Taiwan, 2006-2007.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Cefotaxime; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Penicillins; Quinolines; Streptococcus pneumoniae; Taiwan; Vancomycin | 2012 |
Bilateral corneal ulceration in keratoconus.
Topics: Aza Compounds; Collagen; Corneal Stroma; Corneal Ulcer; Cross-Linking Reagents; Doxycycline; Drug Therapy, Combination; Electrocoagulation; Eye Infections, Bacterial; Fluoroquinolones; Humans; Keratoconus; Male; Middle Aged; Moxifloxacin; Photosensitizing Agents; Postoperative Complications; Prostheses and Implants; Prosthesis Implantation; Quinolines; Staphylococcal Infections; Vancomycin | 2012 |
Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department.
Topics: Aged; Anterior Eye Segment; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Bacteria; California; Cefuroxime; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Humans; Incidence; Lens Implantation, Intraocular; Moxifloxacin; Phacoemulsification; Postoperative Complications; Quinolines; Vancomycin | 2013 |
Susceptibility of methicillin-resistant Staphylococci clinical isolates to netilmicin and other antibiotics commonly used in ophthalmic therapy.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Chloramphenicol; Drug Resistance; Eye Infections, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Netilmicin; Quinolines; Staphylococcus epidermidis; Tobramycin; Vancomycin | 2013 |
Antibiotic susceptibility of staphylococci isolates from patients with chronic conjunctivitis: including associated factors and clinical evaluation.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Chronic Disease; Conjunctivitis, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Follow-Up Studies; Humans; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Quinolines; Staphylococcal Infections; Staphylococcus; Staphylococcus aureus; Staphylococcus epidermidis; Treatment Outcome; Vancomycin | 2013 |
Preparation of intracameral antibiotics for injection.
Topics: Anterior Chamber; Anti-Bacterial Agents; Aza Compounds; Cefuroxime; Chemistry, Pharmaceutical; Drug Compounding; Fluoroquinolones; Humans; Injections, Intraocular; Moxifloxacin; Quinolines; Vancomycin | 2013 |
Antibiotic choice for the prophylaxis of post-cataract extraction endophthalmitis.
Topics: Aged; Aged, 80 and over; Alberta; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Bacteria; Case-Control Studies; Cataract Extraction; Endophthalmitis; Eye Infections, Bacterial; Female; Fluoroquinolones; Hospitals, Private; Hospitals, Public; Humans; Incidence; Male; Moxifloxacin; Postoperative Complications; Prospective Studies; Quinolines; Vancomycin | 2014 |
Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States, 2011 to 2013.
Topics: Anti-Bacterial Agents; Clindamycin; Clostridioides difficile; Clostridium Infections; Drug Resistance, Multiple, Bacterial; Feces; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ribotyping; United States; Vancomycin; Vancomycin Resistance | 2014 |
Intraocular penetration of systemic antibiotics in eyes with penetrating ocular injury.
Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Corneal Injuries; Endophthalmitis; Eye Injuries, Penetrating; Fluoroquinolones; Gram-Positive Bacterial Infections; Intravitreal Injections; Moxifloxacin; Rabbits; Sclera; Vancomycin; Vitreous Body | 2014 |
Characterization of Clostridium difficile isolates from human fecal samples and retail meat from Pennsylvania.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Cattle; Chickens; Clindamycin; Clostridioides difficile; Drug Resistance, Multiple, Bacterial; Feces; Fluoroquinolones; Gene Deletion; Genes, Bacterial; Genotype; Humans; Meat; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Pennsylvania; Phenotype; Repressor Proteins; Ribotyping; Swine; Vancomycin | 2014 |
Molecular characterization and antimicrobial susceptibilities of Clostridium difficile clinical isolates from Victoria, Australia.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Clostridium Infections; Drug Resistance, Bacterial; Fluoroquinolones; Genetic Variation; Humans; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Vancomycin; Victoria | 2015 |
RX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and Is Active against Intracellular Infections by Gram-Positive (Staphylococcus aureus) and Gram-Negative (Pseudomonas aeruginosa) Bacteria.
Topics: Anti-Bacterial Agents; Ceftazidime; Cells, Cultured; Ciprofloxacin; Daptomycin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Guanidines; Humans; Microbial Sensitivity Tests; Monocytes; Moxifloxacin; Protein Synthesis Inhibitors; Pseudomonas aeruginosa; Pseudomonas Infections; Pyrimidinones; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2015 |
U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Toxins; Clindamycin; Clostridioides difficile; Diarrhea; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Fidaxomicin; Fluoroquinolones; Genes, Bacterial; Humans; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Multiplex Polymerase Chain Reaction; Prohibitins; Sentinel Surveillance; United States; Vancomycin | 2015 |
Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators.
Topics: Aminoglycosides; Anti-Bacterial Agents; Benzimidazoles; Ceftriaxone; Clostridioides difficile; Clostridium Infections; Drug Resistance, Multiple, Bacterial; Fidaxomicin; Fluoroquinolones; Humans; Linezolid; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Phenotype; Pyridines; Ribotyping; Vancomycin | 2016 |
Potency and Sterility of Fortified Tobramycin, Fortified Vancomycin, and Moxifloxacin at 4, 24, and 35°C for 14 Days.
Topics: Anti-Bacterial Agents; Drug Stability; Drug Storage; Eye Infections, Bacterial; Fluoroquinolones; Follow-Up Studies; Humans; Infertility; Keratitis; Microbial Sensitivity Tests; Moxifloxacin; Ophthalmic Solutions; Prospective Studies; Temperature; Time Factors; Tobramycin; Vancomycin | 2016 |
Dropless Cataract Surgery: What Are the Potential Downsides?
Topics: Anti-Infective Agents, Local; Antibiotic Prophylaxis; Drug Compounding; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Glucocorticoids; Humans; Lens Implantation, Intraocular; Moxifloxacin; Ocular Hypertension; Ophthalmic Solutions; Phacoemulsification; Risk Factors; Triamcinolone; Vancomycin | 2016 |
Predominance and high antibiotic resistance of the emerging Clostridium difficile genotypes NAPCR1 and NAP9 in a Costa Rican hospital over a 2-year period without outbreaks.
Topics: Anti-Bacterial Agents; Clindamycin; Clostridioides difficile; Clostridium Infections; Communicable Diseases, Emerging; Costa Rica; Cross Infection; Diarrhea; Disease Outbreaks; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Enterocolitis, Pseudomembranous; Fluoroquinolones; Genes, Bacterial; Genotype; Hospitals; Humans; Microbial Sensitivity Tests; Molecular Typing; Moxifloxacin; Ribotyping; Time Factors; Vancomycin | 2016 |
Comparison of agar dilution and broth microdilution methods for Clostridium difficile antimicrobial susceptibility testing.
Topics: Agar; Anti-Bacterial Agents; Clindamycin; Clostridioides difficile; Fluoroquinolones; Japan; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Vancomycin | 2016 |
Two Clusters of Fluoroquinolone and Clindamycin-Resistant Clostridium difficile PCR Ribotype 001 Strain Recognized by Capillary Electrophoresis Ribotyping and Multilocus Variable Tandem Repeat Analysis.
Topics: Aged; Amino Acid Substitution; Anti-Bacterial Agents; Ciprofloxacin; Clindamycin; Clostridioides difficile; Clostridium Infections; Czech Republic; DNA Gyrase; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Electrophoresis, Capillary; Female; Fluoroquinolones; Gene Expression; Humans; Male; Methyltransferases; Metronidazole; Microbial Sensitivity Tests; Minisatellite Repeats; Moxifloxacin; Multilocus Sequence Typing; Retrospective Studies; Ribotyping; Tertiary Care Centers; Vancomycin | 2017 |
High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Toxins; China; Clostridioides difficile; Clostridium Infections; DNA Gyrase; DNA, Bacterial; Drug Resistance, Bacterial; Fidaxomicin; Fluoroquinolones; Genes, Bacterial; Hospitals, Teaching; Hospitals, University; Humans; Metronidazole; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Multilocus Sequence Typing; Ribotyping; Tigecycline; Vancomycin | 2018 |
Endophthalmitis prophylaxis by intracameral antibiotics: In vitro model comparing vancomycin, cefuroxime, and moxifloxacin.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Cefuroxime; Endophthalmitis; Eye Infections, Bacterial; Humans; Lens Implantation, Intraocular; Lenses, Intraocular; Moxifloxacin; Postoperative Complications; Vancomycin | 2017 |
Child with hypopyon.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Ceftazidime; Corneal Perforation; Diagnosis, Differential; Endophthalmitis; Eye Hemorrhage; Fluoroquinolones; Humans; Infant; Male; Moxifloxacin; Prednisolone; Ultrasonography; Vancomycin | 2017 |
Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from hospitals during a 4-year period in China.
Topics: Anti-Infective Agents; Bacterial Proteins; China; Clindamycin; Clostridioides difficile; Clostridium Infections; Diarrhea; Drug Resistance, Multiple, Bacterial; Erythromycin; Fluoroquinolones; Humans; Metronidazole; Microbial Sensitivity Tests; Molecular Epidemiology; Moxifloxacin; Tertiary Care Centers; Vancomycin | 2018 |
Cellular Pharmacokinetics and Intracellular Activity of Gepotidacin against Staphylococcus aureus Isolates with Different Resistance Phenotypes in Models of Cultured Phagocytic Cells.
Topics: Acenaphthenes; Anti-Bacterial Agents; Azithromycin; Cell Line; Daptomycin; Heterocyclic Compounds, 3-Ring; Humans; Linezolid; Macrolides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Oxacillin; Phagocytes; Staphylococcus aureus; THP-1 Cells; Vancomycin | 2018 |
Molecular characterization, toxin detection and resistance testing of human clinical Clostridium difficile isolates from Lebanon.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Clostridium Infections; Drug Resistance, Multiple, Bacterial; Enterocolitis, Pseudomembranous; Enterotoxins; Feces; Female; Fluoroquinolones; Humans; Lebanon; Male; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Multilocus Sequence Typing; Phenotype; Ribotyping; Vancomycin | 2018 |
The emergence of Clostridium difficile PCR ribotype 078 in piglets in the Czech Republic clusters with Clostridium difficile PCR ribotype 078 isolates from Germany, Japan and Taiwan.
Topics: Amino Acid Substitution; Animals; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Czech Republic; DNA Gyrase; Germany; Japan; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Multilocus Sequence Typing; Ribotyping; Swine; Taiwan; Tetracycline; Vancomycin | 2018 |
Changes in Clostridium (Clostridioides) difficile PCR-Ribotype Distribution and Antimicrobial Resistance in a German Tertiary Care Hospital Over the Last 10 Years.
Topics: Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Drug Resistance, Bacterial; Epidemiological Monitoring; Feces; Germany; Humans; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Ribotyping; Tertiary Care Centers; Vancomycin | 2019 |
Endophthalmitis after dropless (Tri-Moxi injection) cataract surgery.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Cataract Extraction; Drug Combinations; Drug Implants; Drug Resistance, Bacterial; Endophthalmitis; Eye Infections, Bacterial; Glucocorticoids; Humans; Intravitreal Injections; Male; Moxifloxacin; Staphylococcal Infections; Staphylococcus epidermidis; Tobramycin, Dexamethasone Drug Combination; Triamcinolone; Vancomycin; Vitrectomy | 2020 |
Rapid onset of orbital cellulitis after uncomplicated strabismus surgery.
Topics: Administration, Ophthalmic; Ampicillin; Anti-Bacterial Agents; Child; Drug Therapy, Combination; Esotropia; Eye Infections, Bacterial; Humans; Male; Moxifloxacin; Oculomotor Muscles; Ophthalmic Solutions; Orbital Cellulitis; Postoperative Complications; Streptococcal Infections; Streptococcus pyogenes; Sulbactam; Tomography, X-Ray Computed; Vancomycin | 2019 |
Toxicities of and inflammatory responses to moxifloxacin, cefuroxime, and vancomycin on retinal vascular cells.
Topics: Animals; Anti-Bacterial Agents; Cefuroxime; Cell Survival; Cells, Cultured; Endothelial Cells; Esterases; Humans; Interleukin-8; Intravitreal Injections; Mice; Moxifloxacin; Pericytes; Retina; Vancomycin | 2019 |
Aqueous level abatement profiles of intracameral antibiotics: A comparative mathematical model of moxifloxacin, cefuroxime, and vancomycin with determination of relative efficacies.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Aqueous Humor; Bacteria; Cataract Extraction; Cefuroxime; Drug Resistance, Bacterial; Endophthalmitis; Eye Infections, Bacterial; Humans; Microbial Sensitivity Tests; Models, Theoretical; Moxifloxacin; Vancomycin | 2019 |
Methicillin-Resistant Staphylococcus aureus Keratitis: Initial Treatment, Risk Factors, Clinical Features, and Treatment Outcomes.
Topics: Administration, Ophthalmic; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefazolin; Corneal Ulcer; Drug Combinations; Eye Infections, Bacterial; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Retrospective Studies; Risk Factors; Staphylococcal Infections; Tobramycin; Treatment Outcome; Vancomycin | 2020 |
The tcdA-negative and tcdB-positive Clostridium difficile ST81 clone exhibits a high level of resistance to fluoroquinolones: a multi-centre study in Beijing, China.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; China; Ciprofloxacin; Clostridioides difficile; Clostridium Infections; DNA Gyrase; Drug Resistance, Bacterial; Enterotoxins; Fluoroquinolones; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Typing; Moxifloxacin; Vancomycin | 2020 |
Case Report: A Polymicrobial Vision-Threatening Eye Infection Associated with Polysubstance Abuse.
Topics: Administration, Ophthalmic; Adult; Anti-Inflammatory Agents; Antioxidants; Ascorbic Acid; Ceftazidime; Cocaine; Cocaine-Related Disorders; Coinfection; Dopamine Uptake Inhibitors; Doxycycline; Endophthalmitis; Female; Gram-Positive Bacterial Infections; Humans; Keratitis; Kingella; Linezolid; Moxifloxacin; Neisseriaceae Infections; Ophthalmic Solutions; Prednisone; Propionibacterium acnes; Streptococcal Infections; Streptococcus; Substance Abuse, Intravenous; Tobramycin; Vancomycin; Voriconazole | 2020 |
Commentary: Intravitreal moxifloxacin for acute postoperative endophthalmitis: Is it as safe and efficacious as the age-old recommended intravitreal vancomycin and ceftazidime?
Topics: Cataract; Ceftazidime; Endophthalmitis; Humans; Intravitreal Injections; Moxifloxacin; Vancomycin | 2021 |
Streptococcus pneumoniae endophthalmitis: clinical settings, antibiotic susceptibility, and visual outcomes.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cataract; Cataract Extraction; Ceftriaxone; Cefuroxime; Corneal Ulcer; Endophthalmitis; Eye Enucleation; Eye Injuries; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Penicillins; Pneumococcal Infections; Retrospective Studies; Severity of Illness Index; Streptococcus pneumoniae; Taiwan; Tertiary Care Centers; Trabeculectomy; Treatment Outcome; Vancomycin; Vitrectomy | 2021 |
Antimicrobial resistance progression in the United Kingdom: A temporal comparison of Clostridioides difficile antimicrobial susceptibilities.
Topics: Anti-Bacterial Agents; Clindamycin; Clostridioides difficile; Clostridium Infections; Drug Resistance, Bacterial; Erythromycin; Humans; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; United Kingdom; Vancomycin | 2021 |
A tale of orbital cellulitis and retinopathy of prematurity in an infant: First case report.
Topics: Cefixime; Child; Female; Gestational Age; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Moxifloxacin; Ophthalmic Solutions; Orbital Cellulitis; Retina; Retinopathy of Prematurity; Vancomycin | 2022 |
Corynebacterium Keratitis: Pure Versus Mixed Infection and Antibiotic Susceptibility Patterns From Different Tertiary Eye Care Centers.
Topics: Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Coinfection; Corynebacterium; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Keratitis; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Retrospective Studies; Tertiary Care Centers; Vancomycin | 2022 |
ENDOPHTHALMITIS IN OPHTHALMOLOGICAL REFERRAL CENTRE IN COLOMBIA: AETIOLOGY AND MICROBIAL RESISTANCE.
Topics: Adult; Anti-Bacterial Agents; Colombia; Endophthalmitis; Eye Infections, Bacterial; Female; Humans; Imipenem; Male; Moxifloxacin; Referral and Consultation; Retrospective Studies; Vancomycin | 2022 |
Reference Susceptibility Testing and Genomic Surveillance of Clostridioides difficile, United States, 2012-17.
Topics: Anti-Bacterial Agents; Clindamycin; Clostridioides; Clostridioides difficile; Clostridium Infections; Genomics; Humans; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Ribotyping; United States; Vancomycin | 2023 |
Antibiotic susceptibility and biofilm-forming ability of Veillonella strains.
Topics: Ampicillin; Anti-Bacterial Agents; Biofilms; Cefoxitin; Clindamycin; Humans; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Piperacillin; Tazobactam; Tetracyclines; Vancomycin; Veillonella | 2022 |
Intravitreal triple therapy with vancomycin, ceftazidime, and moxifloxacin for bacterial endophthalmitis: A Twelve-year experience.
Topics: Anti-Bacterial Agents; Ceftazidime; Endophthalmitis; Eye Infections, Bacterial; Humans; Moxifloxacin; Retrospective Studies; Vancomycin; Vitreous Body | 2023 |